FDA Safety Update on JAK Inhibitors - bottom line on the Tofactitinib Post-Marketing (PMR) study published Sept 1st (cancer higher rates of lung CA and lymphoma with both doses of Tofa vs TNFi) #ACR21 https://t.co/UGbiTGVpgW